Analysis of neovasculature in uveal melanoma by targeting the TGFβ-binding receptor endoglin: Is there prognostic relevance of proliferating endothelium?

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 244, Issue 9, 2006, Pages 1124-1131

  Ziemssen, Focke ^a   Wegner, Rayime ^a   Wegner, Jürgen ^a   Tatar, Olcay ^a   Süsskind, Daniela ^a   Gelisken, Faik ^a   Rohrbach, Martin ^a   Bartz Schmidt, Karl U ^a   Grisanti, Salvatore ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Endoglin; Endothelial cells; Microvascular density; Proliferative activity; Uveal melanoma

Indexed keywords

ENDOGLIN; KI 67 ANTIGEN; PARAFFIN; TRANSFORMING GROWTH FACTOR BETA; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER MORTALITY; CAUSE OF DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; KAPLAN MEIER METHOD; MALE; METASTASIS; OBSERVER VARIATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANK SUM TEST; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OBSERVER VARIATION; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS; VON WILLEBRAND FACTOR;

EID: 33747637717     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-005-0135-z     Document Type: Article

References (42)

1. Altamente M, Montagner R, Fonsatti E, Coalizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M (1996) Expression and structural features of endoglin (CD105), a transforming growth factor b1 and b3 binding protein, in human melanoma. Br J Cancer 74:1586-1591
2. Barbara NP, Wrana JL, Letarte M (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 274:584-594
3. Barbareschi M, Weidner N, Gasparini G, Morelli L, Forti S, Eccher C, Fina P, Caffo O, Leopardi E, Mari F, Bevilacqua P, Dalla Palma P (1995) Appl Immunochem 3:75-84
4. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (1998) Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 18:2701-2710
5. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761
6. Buhring HJ, Muller CA, Letarte M, Gougos A, Saalmuller A, van Agthoven AJ, Busch FW (1991) Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 5:841-847
7. Chang YS, Di Tomaso E, McDonald EM, Jones R, Jain RK, Munn LL (2000) Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci 97:14608-14613
8. Chen X, Maniotis AJ, Majumdar D, Pe'er J, Folberg R (2002) Uveal melanoma cell staining for CD34 and assessment of tumour vascularity. Investig Ophthalmol Vis Sci 43:2533-2539
9. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C (2004) Prediction of metastasis risk using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer. Br J Cancer 90:1216-1221
10. Dawn G, MacKie RM (2002) Expression of endoglin in human melanocytic lesion. Clin Exp Derm 27:153-156
11. Derbyshire E, Thrope P (1997) Targeting the tumour endothelium using specific antibodies. In: Bicknell R, Lewis C, Ferrara N (eds) Tumour angiogenesis. Oxford University Press, Oxford, pp 343-356
12. Derrynk R, Feng XH (1997) TGF-beta receptor signaling. Biochim Biophys Acta 1333:105-150
13. Edel M, Robbins P, D'Antuono M, Harvey J, Papadimitrion J, Mitchell C, Dawkins H (2000) Assessment of endothelial cell proliferation in primary breast carcinoma and its association with axillary lymph node status. Breast 9:28-34
14. Fleiss JL (1971) Measuring scale agreement among many raters. Psychol Bull 76:378-382
15. Folberg R, Rummelt V, Parys-van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, Gruman LM (1993) The prognostic value of tumour blood vessel morphology in primary uveal melanoma. Ophthalmol 1993:1389-1398
16. Folberg R (1997) Discussion of paper by Foss et al. Br J Ophthalmol 81:247-248
17. Folberg R, Maniotis AJ (2004) Vasculogenic mimicry. APMIS 112:508-525
18. Folkman J (1971) Tumour angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186
19. Fonsatti E, Maio M (2004) Highlights on endoglin (CD105); form basic findings towards clinical applications in human cancer. J Transl Med 2:18-24
20. Foss AJE, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S (1996) Microvessel count predicts survival in uveal melanoma. Cancer Res 56:2900-2903
21. Fox SB, Harris AL (2004) Histological quantification of tumour angiogenesis. APMIS 112:413-430
22. Gougos A, Letarte M (1988) Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141:1925-1933
23. Gougos A, LeTarte M (1990) Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265:8361-8364
24. Griffioen AW, Damen CA, Blijham GH, Groenewegen G (1996) Endoglin/CD105 may not be an optional tumour endothelial treatment target. Breast Cancer Res Treat 39:239-240
25. Grisanti S, Canbek S, Kaiserling E, Adam A, Lafaut B, Gelisken F, Szurman P, Henke-Fahle S, Oficjalska-Mlynczak J, Bartz-Schmidt KU (2004) Expression of endoglin in choroidal neovascularization. Exp Eye Res 78:207-213
26. Hoang MP, Selim MA, Bentley RC, Burchette JL, Shea CR (2001) CD34 expression in desmoplastic melanoma. J Cutan Pathol 28:508-512
27. Kumar S, Wang JM, Bernabeu C (1996) CD 105 and angiogenesis. J Pathol 178:363-366
28. Letarte M, Greaves A, Vera S (1995) CD105 (endoglin). In: Schlossman SF, Baumsell L, Gilks W (eds) Leukocyte typing. Oxford University Press, Oxford, pp. 1756-1759
29. Lane AM, Egan KM, Yang J, Saornil MA, Alroy J, Albert D, Gragoudas ES (1997) An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma. Melanoma Res 7:237-242
30. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S (2003) Both high intratumoural microvessel density determined using CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 88:1424-1431
31. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T (1999) Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Investig Ophthalmol Vis Sci 40:2471-2480
32. McDonald DM, Munn L, Jain RK (2000) Vasculogenic mimicry: How convincing, how novel and how significant? Am J Pathol 156:383-388
33. Pezzella F (2000) Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Lancet 355:17878
34. Risau W (1995) Differentiation of endothelium. FASEB J 9:926-933
35. Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA (2003) Significance of CD105 expression for tumour Angiogenesis and prognosis in endometrial carcinoma. APMIS 111:1011-1018
36. Schaling DF, Van der Pol JP, Schlingemann RO, Parys-van Ginderdeuren R et al (1999) Vascular density and vascular patterns in the prognosis of choroidal melanoma. In: Schaling DF (ed) Radionuclides and radiolabeled antibodies in choroidal melanoma (diagnosis and therapy). Rijksuniversiteit te Leiden, Leiden, pp. 43-54
37. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, Seftor REB, Hendrix MJC (2002) Expression of multiple molecular phenotypes by aggressive melanoma tumour cells: Role in vasculogenic mimicry. Crit Rev Onc 44:17-27
38. Seon BK, Matsuno F, Haruta Y, Kondo M, Bareas M (1997) Long-lasting complete inhibition of human solid tumours in SCID mice by targeting endothelial cells of tumour vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3:1031-1044
39. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H (2001) Evaluation of Angiogenesis in non-small cell lung-cancer: Comparison between anti-CD34 antibody and anti-CD 105 antibody. Clin Cancer Res 7:3410-3415
40. Thorpe PE, Burrows FJ (1995) Antibody-directed targeting of the vasculature of solid tumours. Breast Cancer Res Treat 36:237-251
41. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A (2002) Endoglin is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51:268-275
42. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J (1994). Mechanism of activation of the TGF-β receptor. Nature 370:341-347